• Luisa Carbognin, Jenny Furlanetto, Cecilia Vicentini, Rolando Nortilli, Sara Pilotto, Matteo Brunelli, Francesca Pellini, Giovanni Paolo Pollini, Emilio Bria, and Giampaolo Tortora.
• Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, P.le L.A. Scuro 10, 37124, Verona, Italy. emilio.bria@univr.it.
• Anticancer Agents Med Chem. 2015 Jan 1; 15 (1): 15-25.

AbstractNeoadjuvant therapy for triple negative breast cancer (TNBC) has recently generated growing interest given the more aggressive biologic characteristics of such subtype and the lack of approved targeted therapies. Systemic chemotherapy represents the mainstay of treatment for TNBC. Although neoadjuvant chemotherapy has consistently demonstrated higher response rates for TNBC compared to non-TNBC, and the pathological complete response predicts long-term outcome, most patient display residual disease with a higher risk of relapse. In order to improve the outcome of TNBC new chemotherapic combinations, including platinum agents, and different targeted agents such as antiangiogenetics, poly-ADP ribose polymerase (PARP) inhibitors and other small molecule inhibitors are being evaluated in neoadjuvant setting. Currently, the research is ongoing to further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and to individualize the treatment. In this regard, the neoadjuvant setting may represent the best potential scenario to assess the activity and the sensitivity of novel agents.

13 keywords...

hide…